Talk:3-Methylmethcathinone

Comments

Somebody please fix the references and add the images, I'm too lazy for that. Otto von Bismarck 420 (talk) 21:04, 5 May 2021 (UTC)[reply]

Dead link

The first source for the critical review by the WHO is a dead link. 2A04:CEC0:1058:F3B2:F4AA:EC64:C2D9:635A (talk) 17:42, 17 August 2022 (UTC)[reply]

@2A04:CEC0:1058:F3B2:F4AA:EC64:C2D9:635A Saved from archive. -Lemonaka‎ 14:55, 24 October 2023 (UTC)[reply]

Dubious references

The sentence "The company has filed for patent coverage in Canada, Mexico, Croatia, USA, Morroco, Japan, Brazil, Poland, Hungary, Korea, Europe." was removed on the grounds that the writer of the sentence was "Not Providing a Reliable Source". This must be an oversight since no source can be more reliable that the U.N. based WIPO. The document published by this most reliable institution is pointed to by reference [17] and the words "menstrual symptoms" which link to the same document that says: Worldwide applications 2020 KR MA CN HU US BR CA PL EP JP AU HR MX WO 2022 IL ZA 2023 US. I have simply expanded the short form of each country to the full name.

I do not believe the article cited in support of the claim: "3-MMC strongly binds to serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors. In addition, 3-MMC binds weakly to the α1A and α2A adrenergic receptors" mentions 3-MMC at all.

With new, understudied drugs there is a lot we don't know but it's dangerous to pretend that we do and just throw legitimate sounding sources up. Astrovisionkypri (talk) 02:34, 22 September 2023 (UTC)[reply]

So, you are asking for removal of 3-MMC strongly binds to serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors. In addition, 3-MMC binds weakly to the α1A and α2A adrenergic receptors right? -Lemonaka‎ 14:56, 24 October 2023 (UTC)[reply]